<DOC>
	<DOCNO>NCT00896467</DOCNO>
	<brief_summary>RATIONALE : Gathering information patient receive treatment metastatic cancer participate phase II phase III randomize clinical trial patient receive standard treatment off-trial may help doctor learn psychological emotional result clinical trial . PURPOSE : This clinical trial compare psychological emotional impact participate randomized clinical trial impact standard treatment patient metastatic cancer .</brief_summary>
	<brief_title>Psychological Emotional Impact Patients Undergoing Treatment For Metastatic Cancer Either Clinical Trial Standard Off-Trial Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare psychological emotional consequence patient underwent first-line antitumor treatment ( chemotherapy target therapy ) metastatic disease participate phase II III randomize clinical trial v patient underwent standard first-line treatment off-trial . Secondary - To measure compare temporal variation psychological emotional consequence completion stop treatment . - To measure compare degree knowledge implication participate clinical study vs benefit standard off-trial treatment evaluate impact psychological emotional experience . - To evaluate relationship use adjustment strategy emotional regulation psychological emotional experience situation . OUTLINE : This multicenter study . Patients complete four questionnaire , include assessment symptom anxiety depression ( HADS ) , quality life ( QLQ-30 ) , adjustment strategy ( WCC ) , regulation emotional behavior ( ERQ ) , first course treatment , first evaluation treatment effectiveness , one week completion treatment . During first evaluation , patient also complete questionnaire modality randomize clinical trial impact care ( ICEC-R ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cancer Metastatic disease median progressionfree survival â‰¥ 4 month Breast , digestive , kidney , lung Receiving firstline antitumor therapy ( i.e. , chemotherapy target therapy ) part either : Phase II III randomize clinical trial Standard treatment offtrial PATIENT CHARACTERISTICS : WHO performance status ( PS ) 03 Karnofsky PS 50100 % No psychological physical inability respond questionnaire PRIOR CONCURRENT THERAPY : See Disease Characteristics No psychotropic treatment , except antidepressant , anxiolytic , sleep pill take 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>anxiety disorder</keyword>
	<keyword>depression</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>stage IV anal cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>small intestine cancer</keyword>
</DOC>